Methods and compositions to alter the cell surface expression of phosphatidylserine and other clot-promoting plasma membrane phospholipids
AssigneeBlood Center Research Foundation
InventorsTherese Wiedmer, Peter J. Sims
Life of this patent
Estimating the term…
Abstract
A protein preparation that mediates Ca+2 transbilayer movement of phospholipid is disclosed. Additionally, a modified or mutated protein preparation, wherein the protein has a reduced ability to mediate transbilayer movement, is disclosed. In a preferred form of the invention, the protein has been modified such that post-translational modification can no longer occur.
Claims29
An isolated preparation of phospholipid scramblase, wherein the protein is approximately 35 Kd as measured on a 12.5% SDS-polyacrylamide gel under reducing conditions, wherein the scrambles is a naturally occuring phospholipids scramblase.
A recombinant DNA sequence encoding PL scramblase, wherein the sequence is SEQ ID NO:1.
An isolated DNA sequence comprising nucleotides 211-1164 of SEQ ID NO:1.
An isolated DNA sequence comprising nucleotides 463-1137 sequence ID NO:1.
An isolated DNA sequence wherein the sequence is SEQ ID NO:3.
An isolated DNA sequence comprising nucleotides 192-1112 of SEQ ID NO:3.
An isolated DNA sequence comprising nucleotides 438-112 of SEQ ID NO:3.
An isolated DNA sequence wherein the sequence is SEQ ID NO:1 and wherein the sequence is part of a protein expression vector.
An isolated DNA sequence comprising nucleotides 211-1164 of SEQ ID NO:1 and wherein the sequence is part of a protein expression vector.
An isolated DNA sequence comprising nucleotides 463-1137 of SEQ ID NO:1 and wherein the sequence is part of a protein expression vector.
An isolated DNA sequence wherein the sequence is SEQ ID NO:3 and wherein the sequence is part of a protein expression vector.
An isolated DNA sequence wherein the sequence comprises 192-1112 of SEQ ID NO:3 and wherein the sequence is part of a protein expression vector.
An isolated DNA sequence comprising nucleotides 438-1112 of SEQ ID NO:3 and wherein the sequence is part of a protein expression vector.
A recombinant DNA sequence encoding PL scramblase, wherein the sequence has been modified to prevent post-translational modification in the encoded PL scramblase and wherein the sequence comprises a mutation with a non-functional equivalent substitution of residue Thr161 of SEQ ID NO:2;
- Thr159 of SEQ ID NO:4 or the equivalent residue in the conserved region of another PL scramblase.
A recombinant DNA sequence encoding PL scramblase, wherein the sequence has been modified to prevent post-translational modification in the encoded PL scramblase and wherein the sequence comprises at least one non-functional equivalent substitution within residues Asp273-Asp284 of SEQ ID NO:2;
- Asp271-Asp282 of SEQ ID NO:4 or the equivalent residue in the conserved region of another PL scramblase.
A recombinant DNA sequence encoding PL scramblase, wherein the sequence has been modified to prevent post-translational modification in the encoded PL scramblase and wherein the sequence comprises a mutation at Cys297 of SEQ ID NO:2 or the equivalent residue in the conserved region of another PL scramblase.
A method of inhibiting expression of the coagulant properties of the plasma membrane of a cell comprising the step of expressing in the cell plasma membrane a mutant PL scramblase, wherein the PL scramblase has a reduced activity in mediating transmembrane movement of plasma membrane phospholipids, and wherein the mutant phospholipid scramblase comprises a non-functionally equivalent substitution at residue Thr161 of SEQ ID NO:2;
- Thr159 of SEQ ID NO:4 or the equivalent residue in the conserved region of-another PL scramblase.
A method of inhibiting expression of the coagulant properties of the plasma membrane of a cell comprising the step of delivering in the cell plasma membrane a mutant PL scramblase, wherein the PL scramblase has a reduced activity in mediating transmembrane movement of plasma membrane phospholipids, and wherein the mutant phospholipid scramblase comprises a non-functionally equivalent substitution of a cysteine residue wherein the cysteine residue to be substituted is Cys297 of SEQ ID NO:2 or Cys295 of SEQ ID NO:4.
A method of inhibiting expression of the coagulant properties of the plasma membrane of a cell comprising the step of delivering in the cell plasma membrane a mutant PL scramblase, wherein the PL scramblase has a reduced activity in mediating transmembrane movement of plasma membrane phospholipids, and wherein the mutant phospholipid scramblase comprises a non-functionally equivalent substitution of at least one of the residues located in the region of Asp273-Asp284 of SEQ ID NO:2;, Asp271-Asp282 of SEQ ID NO:4 or the equivalent residues in the conserved region of another PL scramblase.
A method of inhibiting expression of the coagulant properties of the plasma membrane of a cell comprising the step of delivering in the cell plasma membrane a mutant PL scramblase, wherein the PL scramblase has a reduced activity in mediating transmembrane movement of plasma membrane phospholipids, and wherein the mutant phospholipid scramblase comprises a non-functionally equivalent substitution of at least one residue selected from the group consisting of Asp273, Asp275, Phe277, Ile279, Phe281, and Asp284 of SEQ ID NO:2;
- and Asp271, Asp273, Phe275, Ile277, Phe279, and Asp282 of SEQ ID NO:4.
Dependencies are inferred from the claim text.